Global Blood Therapeutics is biopharmaceutical firm that develops therapeutics for blood-based disorders. Its lead product candidate is GBT440, a once-daily oral prophylactic therapy for sickle cell disease (SCD), currently in Phase 1/2 development. GBT440 also being developed for the treatment of acute and chronic hypoxemic(inadequate levels of oxygen in the blood) pulmonary disorders. Additionally, its pipeline includes several small molecule kallikrein inhibitors for the prevention of angioedema attacks. SCD affects ~100K Americans and ~60K Europeans each year. The global incidence is ~300K per year. 2014 Financials ($M): Operating Expenses: 20.5 (+31.0%); Net Loss: (20.8) (-14.9%); Cash Burn: (20.1) (-36.9%).